<DOC>
	<DOCNO>NCT02164942</DOCNO>
	<brief_summary>This prospective , single arm , observational study examine aurora kinase circulate tumor cell subject bladder cancer treat standard cisplatin-based chemotherapy .</brief_summary>
	<brief_title>LCI-GU-BLA-SPEC-001 : Aurora Kinase Expression Muscle-Invasive Bladder Cancer</brief_title>
	<detailed_description>Subjects receive neoadjuvant cisplatin-based chemotherapy follow radical cystectomy per standard care . CTC Aurora kinase expression pattern analyze subject specimen correlation clinicopathologic outcome . Subjects study total five year follow cystectomy .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Histologically confirm American Joint Committee Cancer seventh edition clinical stage T24a N03 urothelial carcinoma bladder base diagnostic transurethral bladder biopsy transurethral resection bladder tumor ( TURBT ) confirm presence urothelial carcinoma muscularis propria invasion . Archived tissue prior biopsy/resection must available baseline AK analysis . Subjects must eligible undergo radical cystectomy cisplatinbased chemotherapy . Subjects radiographically enlarge lymph node ( short axis &gt; 10 mm CT scan MRI ) undergo percutaneous biopsy stag accordance local practice , though preferred , mandatory study enrollment . A baseline compute tomography ( CT ) scan intravenous contrast chest , abdomen pelvis require subject . A radionuclide bone scan also required subject skeletal pain abnormally elevate alkaline phosphatase value . Age least 18 year old . ECOG performance status 0 1 . Bilirubin le 1.5 mg/dL . Subjects must adequate liver function : AST ALT le 2.5x upper limit normal , alkaline phosphatase le 2.5x upper limit normal . Subjects must adequate bone marrow function : Platelets great 100,000 cells/mm3 , Hemoglobin great 9.0g/dL ANC great 1,500 cells/mm3 . Subjects must adequate renal function creatinine clearance least 60 mL/min . Subjects must sign write informed consent document authorization release medical record purpose research . Exclusion Criteria Pure nonurothelial mixed small cell histology identify within TURBT specimen . Absence document urothelial carcinoma muscularis propria invasion diagnostic transurethral bladder biopsy transurethral resection bladder tumor ( TURBT ) . Distant metastatic disease , include nonregional lymphadenopathy visceral metastasis , identify pretreatment radiographic study . Creatinine clearance le 60 mL/min . CTCAE version 4 grade 2 great hearing loss . CTCAE version 4 grade 2 great peripheral neuropathy . NYHA class III heart failure cardiac ejection fraction less equal 50 % . Women childbearing age pregnant breast feeding . Uncontrolled current illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Subjects active malignancy define synchronous malignancy time bladder cancer diagnosis , exclude nonmetastatic , nonmelanoma skin cancer exclude . Major surgery within 4 week consent . Subjects require therapeutic anticoagulation time consent . Currently enrol another clinical trial treatment bladder cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>